Vasodilators in pulmonary hypertension

Peacock, A
December 1993
Thorax;Dec1993, Vol. 48 Issue 12, p1196
Academic Journal
No abstract available.


Related Articles

  • Right Ventricular Unloading: Lessons from the Left. Pranciosa, Joseph A.; Fischer, Herbert A. // Annals of Internal Medicine;Nov81, Vol. 95 Issue 5, p647 

    Editorial. Comments on the adverse hemodynamic effects of phentolamine in primary pulmonary hypertension. Effect of vasodilators on pulmonary vascular resistance; Mechanism of action of vasodilators.

  • Oral agents in the treatment of PAH. Le, Aileen; Jaekyu Shin // Cardiology Today;Nov2013, Vol. 16 Issue 11, p12 

    The article discusses recent research examining the effectiveness of oral vasoconstrictors and vasodilators in treating pulmonary arterial hypertension.

  • Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Fukumoto, Y.; Matoba, T.; Ito, A.; Tanaka, H.; Kishi, T.; Hayashidani, S.; Abe, K.; Takeshita, A.; Shimokawa, H. // Heart;Mar2005, Vol. 91 Issue 3, p391 

    Presents a letter to the editor related to acute vasodilator effects of fusadil in patients with severe pulmonary hypertension.

  • Nitric oxide can save lives.  // Nutrition Health Review: The Consumer's Medical Journal;1994, Issue 71, p7 

    Reports on the physiological effect of nitric oxide. Vasodilation; Prevention of pulmonary hypertension; Oxygenation facilitator; Mechanism of action in the bloodstream.

  • Immediate and Long-term Hemodynamic and Clinical Effects of Sildenefil in Patients With Pulmonary Arterial Hypertension Receiving Vasodilator Therapy. Bhatia, Sundeep; Frantz, Robert P.; Severson, Cathy J.; Durst, Louise A.; McGoon, Michael D. // Mayo Clinic Proceedings;Oct2003, Vol. 78 Issue 10, p1207 

    Determines the immediate and long-term effects of adding sildenefil, a phosphodiesterase-5 inhibitor to the medical regimen of patients with pulmonary arterial hypertension (PAH). Pulmonary vasodilator effect in patients already receiving vasodilators for PAH.

  • Vasodilators and Prostaglandin Inhibitors in Primary Pulmonary Hypertensions. Hermiller, James B.; Bambach, Dennis; Thompson, Michael J.; Huss, Patricia; Fontana, Mary E.; Magorien, Raymond D.; Unverferth, Donald V.; Leier, Carl V. // Annals of Internal Medicine;Oct82, Vol. 97 Issue 4, p480 

    Deals with a study which determined and compared the resting hemodynamic effects of various vasodilator agents and prostaglandin inhibitors in patients with primary pulmonary hypertension. Background on primary pulmonary hypertension; Patient population; Baseline hemodynamic data; Discussion...

  • New Drugs: Respiratory and allergic disease. II. Chronic obstructive airways disease and respiratory infections. Chung, K. Fan; Barnes, Peter J. // British Medical Journal (Clinical Research Edition);1/9/1988, Vol. 296 Issue 6615, p111 

    Examines the effects of pulmonary vasodilators on the reduction of pulmonary hypertension of chronic obstructive airways. Stimulation of the carotid body by almitrine bismesylate; Improvement of chest infections; Inhibitions of the pulmonary vasoconstriction by the calcium antagonists.

  • Multiple drugs.  // Reactions Weekly;3/9/2013, Issue 1443, p28 

    An abstract of the article "Nonketotic hyperglycinemia presenting as pulmonary hypertensive vascular disease and fatal pulmonary edema in response to pulmonary vasodilator therapy," by J. J. Menendez Suso and Molina and colleagues that was published in the September 2012 issue is presented.

  • Acute Vasodilator Responsiveness and Microvascular Recruitment in Idiopathic Pulmonary Arterial Hypertension. Langleben, David; Orfanos, Stylianos E.; Giovinazzo, Michele; Schlesinger, Robert D.; Hirsch, Andrew M.; Blenkhorn, Fay; Lesenko, Lyda x; Armaganidis, Apostolos; Catravas, John D. // Annals of Internal Medicine;1/20/2015, Vol. 162 Issue 2, p154 

    The article offers information on the study of hemodynamic response to an acute vasodilator challenge in Idiopathic pulmonary arterial hypertension (IPAH) resulting in reduction of pulmonary arterial pressure and decrease in pulmonary arterial blood flow. Topics discusses the heart...

  • 731 Benefit of vasodilator treatment in pulmonary arterial hypertension related to HIV-infection (PAHRH). Konorza, T.; Krings, P.; Neumann, T.; Kondratieva, J.; Erbel, R. // European Journal of Heart Failure. Supplements;Jun2006, Vol. 5 Issue 1, p170 

    An abstract of the study "Benefit of Vasodilator Treatment in Pulmonary Arterial Hypertension Related to HIV-Infection (PAHRH)," by T. Konorza et al. is presented.


Read the Article


Sign out of this library

Other Topics